Investors / United States / Avego
Avego
Venture capital · Alpharetta, GA, United States · North America
Avego is a healthcare investment firm that invests in private and public companies developing and commercializing products and services across the healthcare continuum. It operates through Avego Healthcare Capital, Avego BioScience Capital, and Velan Capital, investing its own capital alongside entrepreneurs and management teams.
Invests inHealthcare & Biotech
In its own wordshealthcarebiotechgrowth capitalpublic marketslife sciences
Your fit with Avego
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsAvego lists 25 checked portfolio companies on its own site and is named in 7 funding rounds, 2 of them as lead. Its most frequent entry is Growth, 50% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 74% of its companies are based in United States. It invests most often alongside RA Capital, Agent Capital and BroadOak Capital Partners.
Counts come from funding rounds that name Avego, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Avego's whole history. Rounds on record name 6 companies; its own site lists 25. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 17% |
| Series B | 33% |
| Growth | 50% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 3 | 1 |
| '26 | 4 | 1 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 60th | 25 companies |
| Recent activity | 82th | 4 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 94th | 24% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 70th | 4 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| RA Capital | 3 |
| Agent Capital | 2 |
| BroadOak Capital Partners | 2 |
| Delos Capital | 2 |
| Forbion | 2 |
| Global BioAccess Fund | 2 |
| Jeito Capital | 2 |
| Longitude Capital | 2 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers2496%
- No longer answers00%
- Points to another company14%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherCompare Avego head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Avego| Date | Company | Stage |
|---|---|---|
| 29 Oct 2026 | Series C+ Led | |
| 6 May 2026 | Series C+ | |
| 27 Jan 2026 | Series B | |
| 8 Jan 2026 | Series A | |
| 11 Nov 2025 | Series B Led | |
| 28 Jul 2025 | Series C+ | |
| 19 May 2025 | Series C+ |
Round details for Avego
Amounts, full round histories and every co-investor in Avego's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
25 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Alentis Therapeutics is a clinical-stage biotech company that treats cancer and reverses fibrosis by developing anti-Claudin-1 antibody-drug conjugates and monoclonal antibodies | Healthcare & Biotech | Portfolio page | ||
| The company operates a pharmacy that delivers prescriptions and offers 24/7 support | Healthcare & Biotech | Portfolio page | ||
| Alveus Therapeutics develops treatments for obesity and weight loss maintenance | Healthcare & Biotech | Jan 2026Series A | Page + round | |
| Antios Therapeutics develops innovative therapies to treat and cure hepatitis B virus and other viral diseases. | Healthcare & Biotech | Portfolio page | ||
| Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines | Healthcare & Biotech | Portfolio page | ||
| AtomVie offers services for the cGMP manufacturing and global distribution of radiopharmaceuticals | Healthcare & Biotech | Portfolio page | ||
| Caribou Biosciences is a clinical-stage biopharmaceutical company focused on developing transformative genome-edited allogeneic cell therapies for devastating human diseases. | Healthcare & Biotech | Portfolio page | ||
| CellCentric develops a drug called inobrodib for the treatment of multiple myeloma and other cancers | Healthcare & Biotech | May 2025Series C+ · 2 rounds | Page + round | |
| Ellie Diagnostics is a full-service veterinary reference laboratory | Healthcare & Biotech | Portfolio page | ||
| Ensho Therapeutics is advancing a potential oral therapy to treat patients with inflammatory bowel disease (IBD). | Healthcare & Biotech | Portfolio page | ||
| EpiBiologics develops medicines that use bispecific antibodies to selectively degrade disease-causing extracellular proteins | Healthcare & Biotech | Portfolio page | ||
| Evommune discovers and develops innovative therapies that target key drivers of chronic inflammatory disease. | Healthcare & Biotech | Portfolio page | ||
| The company uses modern life sciences and machine learning techniques to better predict health outcomes. | Healthcare & Biotech | Portfolio page | ||
| Immunocore develops immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases | Healthcare & Biotech | Portfolio page | ||
| Jasper Therapeutics is developing innovative therapies to treat significant immune-mediated diseases | Healthcare & Biotech | Portfolio page | ||
| MapLight Therapeutics develops innovative therapeutics for brain disorders using a unique discovery platform combining cutting-edge technologies. | Healthcare & Biotech | Jul 2025Series C+ | Page + round | |
| MyTomorrows helps patients find and access treatments, and also provides services for healthcare professionals and BioPharma companies related to clinical trials and expanded access programs. | Healthcare & Biotech | Nov 2025Series B | Page + round | |
| The company designs and provides lab automation products and services, including workstations, modules, and software. | Healthcare & Biotech | Oct 2026Series C+ | Page + round | |
| PBS Biotech develops and manufactures cell therapy manufacturing systems, including bioreactor systems and accessories. | Healthcare & Biotech | Portfolio page | ||
| Saol Therapeutics is a clinical-stage, pharmaceutical company focused on late-stage clinical development in CNS disorders and orphan diseases. | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- avego.com
- Last read
- 5 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 19 May 2025
- Companies checked
- 25
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Avego's profile as data
Pull Avego's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/avego.com
# also
GET /v1/firms/avego.com/portfolio
GET /v1/firms/avego.com/coinvestors
GET /v1/firms/avego.com/news